|
| Study | Site | Vaccine | Volunteers | Vaccine to placebo randomization | Results |
|
| Vax004 | USA and Netherlands | AIDSVAX B/B′ gp120 with alum | 5,100 MSM and 300 women | 2 : 1 | No vaccine efficacy |
|
| Vax003 | Thailand | AIDSVAX B/E gp120 with alum | 2,500 men and women IDUs | 1 : 1 | No vaccine efficacy |
|
| HVTN 502 Step trial | North America, the Caribbean, South America, and Australia | MRKAd5 HIV-1 gag/pol/nef trivalent vaccine based on adenovirus type 5 | 3,000 MSM and heterosexual women and men | 1 : 1 | No vaccine efficacy |
|
| RV144 | Thailand | Recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) and recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E) | 16,402 community-risk men and women | 1 : 1 | 31.2% vaccine efficacy at 42 months |
|
| HVTN 503 Phambili trial | South Africa | MRKAd5 HIV-1 gag/pol/nef trivalent vaccine based on adenovirus type 5 | 801 heterosexual men and women | 1 : 1 | No vaccine efficacy |
|
| HVTN 505 | USA | 6-plasmid DNA vaccine and rAd5 vector boost | 2,504 men or transgender women who have sex with men | 1 : 1 | No vaccine efficacy |
|
| HIV-V-A004 | USA, Rwanda, South Africa, Thailand, and Uganda | Homologous Ad26 mosaic vector regimens or Ad26 mosaic and MVA mosaic heterologous vector regimens, with high-dose, low-dose or no clade C gp140 protein plus adjuvant | 400 men and women | — | Results awaited |
|
| HVTN 100 | South Africa | Clade C ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 | 252 men and women | 5 : 1 | Results awaited |
|
| HVTN 702 | South Africa | ALVAC-HIV and bivalent subtype C gp120/MF59 | 5,400 men and women | 1 : 1 | Results awaited |
|
| HVTN 703/HPTN 081 | South America and Sub-Saharan Africa | VRC01 broadly neutralizing monoclonal antibody | 2400 MSM and transgender and 1500 women | 2 : 1 | Results awaited |
|
